Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin in women with endometriosis and poor ovarian response
IRCT20091012002576N47Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of atorvastatin in endometriosis and poor ovarian response (POR) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Anti-Müllerian hormone. Started Oct 2024; status: completed.
02
Drugs
atorvastatin
03
Conditions
endometriosispoor ovarian response (POR)
Beyond the preview
Go deeper on IRCT20091012002576N47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091012002576N47.